Prevention of vasculopathy by vitamin K supplementation: Can we turn fiction into fact?

Atherosclerosis

Volumn 240, Issue 1, 2015, Pages 10-16

  Brandenburg, Vincent M ^a   Schurgers, Leon J ^b   Kaesler, Nadine ^a   Püsche, Katrin ^a   van Gorp, Rick H ^b   Leftheriotis, Georges ^c   Reinartz, Sebastian ^a   Koos, Ralf ^a   Krüger, Thilo ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c ANGERS UNIVERSITY HOSPITAL   (France)

Author keywords

Anticoagulation; Arteriosclerosis; Matrix gla protein; Vascular calcification; Vitamin K

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR; FARNOQUINONE; MATRIX GLA PROTEIN; MENAQUINONE; OSTEOCALCIN; PHYTOMENADIONE; RIVAROXABAN; UNCLASSIFIED DRUG; VITAMIN K GROUP;

AGATSTON SCORE; ANTICOAGULANT THERAPY; AORTIC CALCIFICATION; ARTERY WALL; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; BLOOD VESSEL WALL; BONE DENSITY; CARBOXYLATION; CARDIOVASCULAR MORTALITY; DIETARY INTAKE; END STAGE RENAL DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMODIALYSIS PATIENT; HUMAN; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; MORTALITY; NONHUMAN; PHENOTYPE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; VASCULAR DISEASE; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; ANIMAL; DIET SUPPLEMENTATION; METABOLISM; PROTECTION; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VASCULAR CALCIFICATION; VASCULAR DISEASES; VITAMIN K DEFICIENCY;

ANIMALS; ANTICOAGULANTS; ATHEROSCLEROSIS; DIETARY SUPPLEMENTS; HUMANS; OSTEOCALCIN; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VASCULAR CALCIFICATION; VASCULAR DISEASES; VITAMIN K; VITAMIN K DEFICIENCY;

EID: 84923928891     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.02.040     Document Type: Review

References (47)

1. Krueger T., Westenfeld R., Schurgers L., Brandenburg V. Coagulation meets calcification: the vitamin K system. Int. J. Artif. Organs 2009, 32(2):67-74.
2. Willems B.A., Vermeer C., Reutelingsperger C.P., Schurgers L.J. The realm of vitamin K dependent proteins: shifting from coagulation toward calcification. Mol. Nutr. Food Res. 2014, 58(8):1620-1635.
3. Trumbo P., Yates A.A., Schlicker S., Poos M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. J.Am. Diet. Assoc. 2001, 101(3):294-301.
4. Inoue T., Fujita T., Kishimoto H., Makino T., Nakamura T., Nakamura T., Sato T., Yamazaki K. Randomized controlled study on the prevention of osteoporotic fractures (OF study): a phase IV clinical study of 15-mg menatetrenone capsules. J.Bone Min. Metab. 2009, 27(1):66-75.
5. Luo G., Ducy P., McKee M.D., Pinero G.J., Loyer E., Behringer R.R., Karsenty G. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 1997, 386(6620):78-81.
6. Price P.A., Faus S.A., Williamson M.K. Warfarin causes rapid calcification of the elastic lamellae in rat arteries and heart valves. Arterioscler. Thromb. Vasc. Biol. 1998, 18(9):1400-1407.
7. Vermeer C. Vitamin K: the effect on health beyond coagulation - an overview. Food Nutr. Res. 2012, 56.
8. Murshed M., Schinke T., McKee M.D., Karsenty G. Extracellular matrix mineralization is regulated locally; different roles of two gla-containing proteins. J.Cell. Biol. 2004, 165(5):625-630.
9. Schurgers L.J., Uitto J., Reutelingsperger C.P. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol. Med. 2013, 19(4):217-226.
10. Geleijnse J.M., Vermeer C., Grobbee D.E., Schurgers L.J., Knapen M.H., van dM I., Hofman A., Witteman J.C. Dietary intake of menaquinone is associated with a reduced risk of coronary heart disease: the Rotterdam Study. J.Nutr. 2004, 134(11):3100-3105.
11. Juanola-Falgarona M., Salas-Salvado J., Martinez-Gonzalez M.A., Corella D., Estruch R., Ros E., Fito M., Aros F., Gomez-Gracia E., Fiol M., Lapetra J., Basora J., Lamuela-Raventos R.M., Serra-Majem L., Pinto X., Munoz M.A., Ruiz-Gutierrez V., Fernandez-Ballart J., Bullo M. Dietary intake of vitamin K is inversely associated with mortality risk. J.Nutr. 2014, 144(5):743-750.
12. Vissers L.E., Dalmeijer G.W., Boer J.M., Monique Verschuren W.M., van der Schouw Y.T., Beulens J.W. Intake of dietary phylloquinone and menaquinones and risk of stroke. J.Am. Heart Assoc. 2013, 2(6):e000455.
13. Shea M.K., Holden R.M. Vitamin K status and vascular calcification: evidence from observational and clinical studies. Adv. Nutr. 2012, 3(2):158-165.
14. Erkkila A.T., Booth S.L. Vitamin K intake and atherosclerosis. Curr. Opin. Lipidol. 2008, 19(1):39-42.
15. Gast G.C., de Roos N.M., Sluijs I., Bots M.L., Beulens J.W., Geleijnse J.M., Witteman J.C., Grobbee D.E., Peeters P.H., van der Schouw Y.T. Ahigh menaquinone intake reduces the incidence of coronary heart disease. Nutr. Metab. Cardiovasc. Dis. 2009, 19(7):504-510.
16. Kruger T., Oelenberg S., Kaesler N., Schurgers L.J., van de Sandt A.M., Boor P., Schlieper G., Brandenburg V.M., Fekete B.C., Veulemans V., Ketteler M., Vermeer C., Jahnen-Dechent W., Floege J., Westenfeld R. Warfarin induces cardiovascular damage in mice. Arterioscler. Thromb. Vasc. Biol. 2013, 33(11):2618-2624.
17. Li Q., Guo H., Chou D.W., Harrington D.J., Schurgers L.J., Terry S.F., Uitto J. Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticum. Am. J. Pathol. 2013, 182(4):1139-1150.
18. Schurgers L.J., Joosen I.A., Laufer E.M., Chatrou M.L., Herfs M., Winkens M.H., Westenfeld R., Veulemans V., Krueger T., Shanahan C.M., Jahnen-Dechent W., Biessen E., Narula J., Vermeer C., Hofstra L., Reutelingsperger C.P. Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype. PLoS One 2012, 7(8):e43229.
19. Schurgers L.J., Spronk H.M., Skepper J.N., Hackeng T.M., Shanahan C.M., Vermeer C., Weissberg P.L., Proudfoot D. Post-translational modifications regulate matrix Gla protein function: importance for inhibition of vascular smooth muscle cell calcification. J.Thromb. Haemost. 2007, 5(12):2503-2511.
20. Schurgers L.J., Spronk H.M., Soute B.A., Schiffers P.M., DeMey J.G., Vermeer C. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K in rats. Blood 2007, 109(7):2823-2831.
21. Moncada R.M., Venta L.A., Venta E.R., Fareed J., Walenga J.M., Messmore H.L. Tracheal and bronchial cartilaginous rings: warfarin sodium-induced calcification. Radiology 1992, 184(2):437-439.
22. Schurgers L.J., Aebert H., Vermeer C., Bultmann B., Janzen J. Oral anticoagulant treatment: friend or foe in cardiovascular disease?. Blood 2004, 104(10):3231-3232.
23. Weijs B., Blaauw Y., Rennenberg R.J., Schurgers L.J., Timmermans C.C., Pison L., Nieuwlaat R., Hofstra L., Kroon A.A., Wildberger J., Crijns H.J. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur. Heart J. 2011, 32(20):2555-2562.
24. Koos R., Mahnken A.H., Muhlenbruch G., Brandenburg V., Pflueger B., Wildberger J.E., Kuhl H.P. Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography. Am. J. Cardiol. 2005, 96(6):747-749.
25. Lerner R.G., Aronow W.S., Sekhri A., Palaniswamy C., Ahn C., Singh T., Sandhu R., McClung J.A. Warfarin use and the risk of valvular calcification. J.Thromb. Haemost. 2009, 7(12):2023-2027.
26. Brandenburg V.M., Sinha S., Specht P., Ketteler M. Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder. Pediatr. Nephrol. 2014, 29(12):2289-2298.
27. Palaniswamy C., Aronow W.S., Sekhri A., Adapa S., Ahn C., Singh T., Malhotra B., Lerner R. Warfarin use and prevalence of coronary artery calcification assessed by multislice computed tomography. Am. J. Ther. 2014, 21(3):148-151.
28. Villines T.C., O'Malley P.G., Feuerstein I.M., Thomas S., Taylor A.J. Does prolonged warfarin exposure potentiate coronary calcification in humans? Results of the warfarin and coronary calcification study. Calcif. Tissue Int. 2009, 85(6):494-500.
29. Schurgers L.J., Spronk H.M. Differential cellular effects of old and new oral anticoagulants: consequences to the genesis and progression of atherosclerosis. Thromb. Haemost. 2014, 112(5).
30. Schurgers L.J., Vermeer C. Differential lipoprotein transport pathways of K-vitamins in healthy subjects. Biochim. Biophys. Acta 2002, 1570(1):27-32.
31. Al Rajabi A., Booth S.L., Peterson J.W., Choi S.W., Suttie J.W., Shea M.K., Miao B., Grusak M.A., Fu X. Deuterium-labeled phylloquinone has tissue-specific conversion to menaquinone-4 among Fischer 344 male rats. J.Nutr. 2012, 142(5):841-845.
32. McCabe K.M., Booth S.L., Fu X., Shobeiri N., Pang J.J., Adams M.A., Holden R.M. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013, 83(5):835-844.
33. Nakagawa K., Hirota Y., Sawada N., Yuge N., Watanabe M., Uchino Y., Okuda N., Shimomura Y., Suhara Y., Okano T. Identification of UBIAD1 as a novel human menaquinone-4 biosynthetic enzyme. Nature 2010, 468(7320):117-121.
34. Karl J.P., Fu X., Dolnikowski G.G., Saltzman E., Booth S.L. Quantification of phylloquinone and menaquinones in feces, serum, and food by high-performance liquid chromatography-mass spectrometry. J.Chromatogr. B Anal. Technol. Biomed. Life Sci. 2014, 963:128-133.
35. Schlieper G., Westenfeld R., Kruger T., Cranenburg E.C., Magdeleyns E.J., Brandenburg V.M., Djuric Z., Damjanovic T., Ketteler M., Vermeer C., Dimkovic N., Floege J., Schurgers L.J. Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J.Am. Soc. Nephrol. 2011, 22(2):387-395.
36. Caluwe R., Vandecasteele S., Van Vlem B., Vermeer C., De Vriese A.S. Vitamin K2 supplementation in haemodialysis patients: a randomized dose-finding study. Nephrol. Dial. Transplant. 2014, 29(7):1385-1390.
37. Westenfeld R., Krueger T., Schlieper G., Cranenburg E.C., Magdeleyns E.J., Heidenreich S., Holzmann S., Vermeer C., Jahnen-Dechent W., Ketteler M., Floege J., Schurgers L.J. Effect of vitamin K2 supplementation on functional vitamin K deficiency in hemodialysis patients: a randomized trial. Am. J. Kidney Dis. 2012, 59(2):186-195.
38. Dalmeijer G.W., van der Schouw Y.T., Magdeleyns E., Ahmed N., Vermeer C., Beulens J.W. The effect of menaquinone-7 supplementation on circulating species of matrix Gla protein. Atherosclerosis 2012, 225(2):397-402.
39. Ketteler M., Rothe H., Brandenburg V.M., Westenfeld R. The K-factor in chronic kidney disease: biomarkers of calcification inhibition and beyond. Nephrol. Dial. Transplant. 2014, 29(7):1267-1270.
40. Krueger T., Schlieper G., Schurgers L., Cornelis T., Cozzolino M., Jacobi J., Jadoul M., Ketteler M., Rump L.C., Stenvinkel P., Westenfeld R., Wiecek A., Reinartz S., Hilgers R.D., Floege J. Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol. Dial. Transplant. 2014, 29(9):1633-1638.
41. Borissoff J.I., Spronk H.M., ten Cate H. The hemostatic system as a modulator of atherosclerosis. N.Engl. J. Med. 2011, 364(18):1746-1760.
42. Kakkos S.K., Kirkilesis G.I., Tsolakis I.A. Efficacy and safety of the new oral anticoagulants dabigatran, rivaroxaban, apixaban, and edoxaban in the treatment and secondary prevention of venous thromboembolism: a systematic review and meta-analysis of phase III trials. Eur. J. Vasc. Endovasc. Surg. 2014, 48(5):565-575.
43. Sardar P., Chatterjee S., Chaudhari S., Lip G.Y. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. J.Am. Geriatr. Soc. 2014, 62(5):857-864.
44. Gomez-Outes A., Terleira-Fernandez A.I., Calvo-Rojas G., Suarez-Gea M.L., Vargas-Castrillon E. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups. Thrombosis 2013, 2013:640723.
45. Patel M.R., Mahaffey K.W., Garg J., Pan G., Singer D.E., Hacke W., Breithardt G., Halperin J.L., Hankey G.J., Piccini J.P., Becker R.C., Nessel C.C., Paolini J.F., Berkowitz S.D., Fox K.A., Califf R.M. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N.Engl. J. Med. 2011, 365(10):883-891.
46. Granger C.B., Alexander J.H., McMurray J.J., Lopes R.D., Hylek E.M., Hanna M., Al Khalidi H.R., Ansell J., Atar D., Avezum A., Bahit M.C., Diaz R., Easton J.D., Ezekowitz J.A., Flaker G., Garcia D., Geraldes M., Gersh B.J., Golitsyn S., Goto S., Hermosillo A.G., Hohnloser S.H., Horowitz J., Mohan P., Jansky P., Lewis B.S., Lopez-Sendon J.L., Pais P., Parkhomenko A., Verheugt F.W., Zhu J., Wallentin L. Apixaban versus warfarin in patients with atrial fibrillation. N.Engl. J. Med. 2011, 365(11):981-992.
47. Connolly S.J., Ezekowitz M.D., Yusuf S., Eikelboom J., Oldgren J., Parekh A., Pogue J., Reilly P.A., Themeles E., Varrone J., Wang S., Alings M., Xavier D., Zhu J., Diaz R., Lewis B.S., Darius H., Diener H.C., Joyner C.D., Wallentin L. Dabigatran versus warfarin in patients with atrial fibrillation. N.Engl. J. Med. 2009, 361(12):1139-1151.